Proteolysis-concentrating on chimeras (PROTACs) and molecular glue degraders (MGDs) are essentially the most maturely designed TPD approaches. During this assessment, we focus on equally preclinical experiments and medical trials to offer a comprehensive summary of the safety and medical efficiency of PROTACs and MGDs in hematologic malignancies ov